Exposure to PARP inhibitors in the presence of a PBRM1 defect further promotes the replication stress, contributing to the accumulation of DNA damage and formation of micronuclei, which leads to the lethality of tumor cells [232]. Here, PBRM1 is linked to neoplasm.